DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims Status
The Amendment filed on 17Jul2026 is acknowledged in which claim(s) 1-16, 18-30, and 32-33 were canceled, and claim(s) 34-47 are new.
Applicant's election with traverse of Group 4 (e.g., claim 17 and amended claim 31) in the reply filed on 17 Jul 2026 is acknowledged. The traversal is on the ground(s) that “the examination of all the claims does not create an undue search burden on the examiner”. This is not found persuasive because the instant application was submitted under 35 USC 371, therefore the requirement for restriction between groups was based on breaking of unity of invention (see MPEP 1893.03(d), MPEP 1850, MPEP 801), and search burden is not an factor considered under unity of invention. The requirement is still deemed proper and is therefore made FINAL.
Claim(s) 40-46 is/are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention (e.g., if included in the previous claim set would have been part of Group 1), there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 17 Jul 2026.
Claim(s) 17, 31, 34-39, 47 is/are currently pending and presented for examination on the merits.
Claim Interpretation
Claim(s) 17, 31, 34-39, 47, recite(s) “…CD8 positive stem-like chronic resource cells…” in line 1. The instant specification does not define said cells. MPEP 2112.01 provides “Where the claimed and prior art products…are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977)…”. Given the above, prior art teaching an identical or substantially identical process (e.g., the instant claimed active method steps) will be considered to teach the “…CD8 positive stem-like chronic resource cells…”.
Claim(s) 37, recite(s) “…wherein resting is in vitro…” in line 1. The instant specification provides multiple embodiments for resting the T cells in vitro [e.g., pg. 5, lines 4-12; etc.]:
PNG
media_image1.png
246
678
media_image1.png
Greyscale
The instant specification is considered to provide a list of examples, and not a closed definition of ‘resting in vitro’. Given the above, the broadest reasonable interpretation (BRI) is considered to include any prior art teachings of containing/maintaining the instant claimed cells in vitro for any amount of time (e.g., in blood collection tube, in culture medium, etc.).
Claim Rejections - 35 USC § 112(b)
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
Claim(s) 17, 31, 34-39, 47 is/are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim(s) 17, 31, 34-39, 47, recite(s) “…have no or low expression of…” in line(s) 7, rendering the claim(s) indefinite. The instant specification does not define low expression. Specifically, it is unclear if the phrase means (1) low expression compared to some unspecified control; (2) low expression based on set gating (e.g., based on some unknown controls); (3) low expression based on subject specific gating (e.g., gating is adjusted for each individual sample); (4) low expression relative to the expression of other surface markers (e.g., compared to the CD8+ signal); or (5) something else. For the purposes of compact prosecution, the phrase will be considered to mean any level of expression. This rejection may be overcome by amending claim(s) 17 as recited to clearly recite the limitation(s) of the instant invention. Claim(s) 31, 34-39, and 47 can overcome this rejection by amending claim(s) 17 as recited above.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 17, 31, 34-39, 47 is/are rejected under 35 U.S.C. 103 as being unpatentable over WO 2020/170231 A1 (hereinafter “WO231”), in view of Krishna et al. (Science 370, 1328–1334 (2020); hereinafter “Krishna”).
CD8+/PD1+/TCF1+/CD44+/TIM3-/CD39- are considered to be “stem-like chronic resource cells” (see claim interpretation above for details).
Regarding instant claim(s) 17, 31, 35, WO231 teaches a method of obtaining a sample and purifying multipotent (e.g., stem-like) T cells [e.g., title, abstract], wherein said multipotent T cells are CD8+/PD1+/CD44+/CD62L+ /CD127+ [e.g., pg. 4, ¶ 3; pg. 43, ¶ 2; figs. 7A-B]. WO231 further teaches that the multipotent T cells express TCF7, which encodes the TCF1 protein, and that expression of TCF7 (e.g., and therefore of TCF1 protein; e.g., cells are CD8+/PD1+/CD44+/CD62L+ /CD127+/TCF1+) is associated with increased stemness of said T cells, and [e.g., pg. 41, ¶ 1; pg. 42, ¶ 1; pg. 43, ¶ 2].
Regarding instant claim(s) 34, WO231 teaches said T cells are expanded [e.g., pg. 49, ¶ 2].
Regarding instant claim(s) 36, WO231 teaches CD127 and CD62L are detected by flow cytometry [e.g., figs. 7A-B].
Regarding instant claim(s) 37-38, WO231 teaches samples were collected in blood tubes and maintained in cell culture medium (e.g., resting in vitro; see claim interpretation above for details) [e.g., pg. 47, ¶ 2; pg. 49, ¶ 2].
Regarding instant claim(s) 39, WO231 teaches the T cell is a CAR T cell [e.g., pg. 14, ¶ 3].
Regarding instant claim(s) 47, WO231 teaches the subject is human [e.g., pg. 14, ¶ 3; fig. 3C].
WO231 does not expressly teach that the T cells are TIM3-/CD39-.
Regarding instant claim(s) 17, 31, 3-39, 47, Krishna teaches that TIM3 and CD39 are inhibitory surface markers on T cells, that adoptive T cell therapies with stem cell like properties are TIM3-/CD39-, and that such CAR T cells exhibit superior anti-tumor responses [e.g., abstract; pg. 1, col. 2, ¶ 1].
It would have been prima facie obvious to a person having ordinary skill in the art (PHOSITA) before the effective filing date of the claimed invention to combine the method of isolating CD8+/PD1+/ CD44+/CD62L+/CD127+/TCF1+ CAR T cells taught by WO231, with the further negative selection of TIM3 and CD39 for CAR T cells as taught by Krishna, to arrive at a method for isolating CD8+/PD1+/CD44+/ CD62L+/CD127+/TCF1+/TIM3-/CD39- T cells. A PHOSITA would have been motivated to combine the method of isolating CD8+/PD1+/CD44+/CD62L+/CD127+/TCF1+ CAR T cells taught by WO231 to include that the CAR T cells are TIM3-/CD39- as taught by Krishna, because WO231 teaches the base isolation method and target population (e.g., phenotype characterized by listed cell markers) of CAR T cells with stem cell like properties, and Krishna further teaches that TIM3-/CD39- CAR T cells exhibit stem cell like properties which superior anti-tumor responses. There would have been a reasonable expectation of success for a PHOSITA to combine the method of isolating CD8+/PD1+/CD44+/CD62L+/CD127+/TCF1+ CAR T cells taught by WO231 to include that the CAR T cells are TIM3-/CD39- as taught by Krishna, because WO231 teaches the base isolation method (e.g., flow cytometry) and target population markers, and Krishna teaches the additional cell surface markers which were detected using flow cytometry [e.g., pg. 1, col. 3, ¶ 2]. This rationale aligns with the principle of applying a known technique to a known method to yield predictable results, supporting a conclusion of obviousness (see MPEP § 2143).
Thus, the invention as a whole is prima facie obvious over the references, especially in the absence of evidence to the contrary.
Conclusion
No claims are currently allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMY M CHATTIN whose telephone number is (571)270-0646. The examiner can normally be reached T-F 0600-1600 PST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at (571) 272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/AMY M. CHATTIN/Examiner, Art Unit 1643
/JULIE WU/Supervisory Patent Examiner, Art Unit 1643